Abstract
Background: Coronary artery disease remains the leading cause of death globally. Dual antiplatelet treatment with aspirin and aP2Y12 receptor significantly reduces thrombotic events. However, antiplatelet drug response displays considerable interindividual variability.
Methods: Genetic factors account for up to 70% of impaired drug response. A number of genes encoding proteins involved in the pharmacokinetic pathway have been found to alter drug response. Results: According to most studies, CYP2C19 gene is the strongest genetic determinant. The novel antiplatelet agents prasugrel and ticagrelor, seem to overcome genetic restrictions but in expense of increased bleeding rates. Achieving a balance between adequate platelet inhibition and bleeding complications is challenging. Conclusion: Genetic screening may provide valuable guidance towards an efficient antiplatelet treatment. However, the lack of randomized controls trials testing the effect of a genotype-guided therapy, forbids the implementation of genetic testing into clinical practice.Keywords: Antiplatelets, atherosclerosis, clopidogrel, coronary artery disease, genetics, polymorphisms.
Current Pharmaceutical Design
Title:Genetics in the Clinical Decision of Antiplatelet Treatment
Volume: 23 Issue: 9
Author(s): Gerasimos Siasos*, Marina Zaromitidou, Evangelos Oikonomou, Manolis Vavuranakis, Vicky Tsigkou, Nikolaos Papageorgiou, Dimitrios Chaniotis, Dimitrios A. Vrachatis, Christodoulos Stefanadis, Athanasios G. Papavassiliou and Dimitrios Tousoulis
Affiliation:
- Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School and Harvard-MIT Biomedical Engineering Center, Massachusetts Institute of Technology, Boston, MA,United States
Keywords: Antiplatelets, atherosclerosis, clopidogrel, coronary artery disease, genetics, polymorphisms.
Abstract: Background: Coronary artery disease remains the leading cause of death globally. Dual antiplatelet treatment with aspirin and aP2Y12 receptor significantly reduces thrombotic events. However, antiplatelet drug response displays considerable interindividual variability.
Methods: Genetic factors account for up to 70% of impaired drug response. A number of genes encoding proteins involved in the pharmacokinetic pathway have been found to alter drug response. Results: According to most studies, CYP2C19 gene is the strongest genetic determinant. The novel antiplatelet agents prasugrel and ticagrelor, seem to overcome genetic restrictions but in expense of increased bleeding rates. Achieving a balance between adequate platelet inhibition and bleeding complications is challenging. Conclusion: Genetic screening may provide valuable guidance towards an efficient antiplatelet treatment. However, the lack of randomized controls trials testing the effect of a genotype-guided therapy, forbids the implementation of genetic testing into clinical practice.Export Options
About this article
Cite this article as:
Siasos Gerasimos *, Zaromitidou Marina , Oikonomou Evangelos , Vavuranakis Manolis , Tsigkou Vicky , Papageorgiou Nikolaos , Chaniotis Dimitrios , Vrachatis A. Dimitrios , Stefanadis Christodoulos , Papavassiliou G. Athanasios and Tousoulis Dimitrios , Genetics in the Clinical Decision of Antiplatelet Treatment, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161226152529
DOI https://dx.doi.org/10.2174/1381612822666161226152529 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Locked Nucleic Acid Holds Promise in the Treatment of Cancer
Current Pharmaceutical Design The Important Role of Potatoes, An Underrated Vegetable Food Crop in Human Health and Nutrition
Current Nutrition & Food Science Monoamine Involvement in the Antidepressant-Like Effect of β-Caryophyllene
CNS & Neurological Disorders - Drug Targets Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research Effect of Curcumin on Serum Cathepsin D in Patients with Metabolic Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Arterial Aging, Metalloproteinase Regulation, and the Potential of Resistance Exercise
Current Cardiology Reviews Therapeutic Use of Nitric Oxide Scavengers in Shock and Sepsis
Current Pharmaceutical Design Controlling the Flow of Energy: Inhibition and Stimulation of the Creatine Transporter
Current Enzyme Inhibition Cholesterol Homeostasis and Liver X Receptor (LXR) in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Vitamin D Metabolites and/or Analogs: Which D for Which Patient?
Current Vascular Pharmacology EarlyVascularAgeing and Hypertension -A New Model for Understanding Cardiovascular Risk
Current Hypertension Reviews Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Development of Tissue Engineered Vascular Grafts
Current Pharmaceutical Biotechnology Protease Inhibitors with Antileishmanial Activity
Current Enzyme Inhibition PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Cardiovascular & Hematological Agents in Medicinal Chemistry Low-Molecular-Weight Heparins in Acute Coronary Syndromes
Current Vascular Pharmacology Vitamin D and the Metabolic Syndrome
Current Vascular Pharmacology Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Use of Total Parenteral Nutrition in Severe Anorexia Nervosa Complicated by a Gastrointestinal Illness
Current Nutrition & Food Science Involvement of Uridine-Nucleotide-Stimulated P2Y Receptors in Neuronal Growth and Function
Central Nervous System Agents in Medicinal Chemistry